Starpharma Holdings Limited Announce New VivaGel(R) Clinical Trial Commences
The Contributions Starpharma Limited (ASX:SPL)(ROSE:SPHRY) declared begin its following clinical trial of VivaGel(R). The Analysis will measure the level an to activity withheld VivaGel(R) after vaginal administration. The Estimation will be a laboratory assay vaginal sample collected up to 24 soon after that, as VivaGel exhibits(R). The Analysis in 12 womans is determined scale of time on which VivaGel(R), saves activity against HIV and HSV-2 (the shingles sexual).
” Value of this short test - that she provides the potential surrogate for of efficiency VivaGel(R) on folk ahead of Phase 3 studies,” said Dr Jackie Fairley, the MAIN Controlling Starpharma. “This will also give the instruction simply how much previously, than sex, which You could enclose VivaGel(R) to prevent the infection,” added Dr Fairley.
The Analysis is conducted in the Centre for Clinical Studies in Meliburne and USA. The National Institutes! Health (NIH).*
The Additional details of the analysis! incl uded in Exhibit 1 in this announcement.
VivaGel(R), is developed as vaginal microbicide for prevention HIV and HSV-2. The Other exhibits VivaGel(R), - also under estimation, including prevention human canadian pharmacy papillomavirus (HPV), contraception and processing bacterial vaginosis (BV).
* THE CONTRACT NIH No.
About Contribution Starpharma Limited
The Contributions Starpharma Limited (ASX:SPL, OTCQX:SPHRY), - a world leader in development dendrimer nanotechnology for pharmaceutical, lifes-sciences and other exhibits. SPL principally is FORMED two operating companies, Starpharma Pty Ltd in Meliburne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. The Products were founded on SPL’s dendrimer technology - already on the market in the form diagnostic element and laboratory reagent.
The Leaden pharmaceutical product development to Companies - VivaGel(R) (the Gel SPL7013), vaginal microbici de to prevent the transfer IIT, including HIV and shingles sexual.
